Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Podar

Showing results (21-30 of 150) with videos related to

Pageof 15
Sort By:
Best Practice & Research. Clinical Haematology|July 20, 2005
Cytokines and signal transductionTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Pharmaceutics|October 26, 2018
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment StrategiesSonia Vallet, Julia-Marie Filzmoser, Martin Pecherstorfer, et al.
Expert Opinion on Pharmacotherapy|February 14, 2012
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesSonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, et al.
Expert Opinion on Therapeutic Targets|June 7, 2005
Targeting signalling pathways for the treatment of multiple myelomaKlaus Podar, Teru Hideshima, Dharminder Chauhan, et al.
Expert Review of Anticancer Therapy|April 13, 2007
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myelomaKlaus Podar, Paul G Richardson, Dharminder Chauhan, et al.
Expert Opinion on Therapeutic Targets|March 23, 2025
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapyRajeshwari Meli, Osman Aksoy, Sonia Vallet, et al.
Expert Opinion on Investigational Drugs|October 10, 2007
The therapeutic role of targeting protein kinase C in solid and hematologic malignanciesKlaus Podar, Marc S Raab, Dharminder Chauhan, et al.
Cancers|April 30, 2021
Pathway-Directed Therapy in Multiple MyelomaLukas John, Maria Theresa Krauth, Klaus Podar, et al.
Cell Cycle (Georgetown, Tex.)|October 7, 2004
Mcl-1 regulation and its role in multiple myelomaSteven Le Gouill, Klaus Podar, Jean-Luc Harousseau, et al.
Cytokine|November 4, 2022
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implicationsOsman Aksoy, Judith Lind, Vincent Sunder-Plaßmann, et al.
Pageof 15

Showing results (21-30 of 150) with videos related to

Sort By:
Pageof 15
Best Practice & Research. Clinical Haematology|July 20, 2005
Cytokines and signal transductionTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Pharmaceutics|October 26, 2018
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment StrategiesSonia Vallet, Julia-Marie Filzmoser, Martin Pecherstorfer, et al.
Expert Opinion on Pharmacotherapy|February 14, 2012
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesSonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, et al.
Expert Opinion on Therapeutic Targets|June 7, 2005
Targeting signalling pathways for the treatment of multiple myelomaKlaus Podar, Teru Hideshima, Dharminder Chauhan, et al.
Expert Review of Anticancer Therapy|April 13, 2007
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myelomaKlaus Podar, Paul G Richardson, Dharminder Chauhan, et al.
Expert Opinion on Therapeutic Targets|March 23, 2025
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapyRajeshwari Meli, Osman Aksoy, Sonia Vallet, et al.
Expert Opinion on Investigational Drugs|October 10, 2007
The therapeutic role of targeting protein kinase C in solid and hematologic malignanciesKlaus Podar, Marc S Raab, Dharminder Chauhan, et al.
Cancers|April 30, 2021
Pathway-Directed Therapy in Multiple MyelomaLukas John, Maria Theresa Krauth, Klaus Podar, et al.
Cell Cycle (Georgetown, Tex.)|October 7, 2004
Mcl-1 regulation and its role in multiple myelomaSteven Le Gouill, Klaus Podar, Jean-Luc Harousseau, et al.
Cytokine|November 4, 2022
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implicationsOsman Aksoy, Judith Lind, Vincent Sunder-Plaßmann, et al.
Pageof 15